In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-γ Agonist Rosiglitazone | Zendy

Tianli Yue | Zendy; Jun Chen | Zendy; Weike Bao | Zendy; Padma Kumar Narayanan | Zendy; Antoine Bril | Zendy; Wen Jiang | Zendy; Paul G. Lysko | Zendy; Juan-Li Gu | Zendy; Rogely Boyce | Zendy; Dawn Zimmerman | Zendy; Timothy K. Hart | Zendy; Robin E. Buckingham | Zendy; Eliot H. Ohlstein | Zendy

Open Access

In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-γ Agonist Rosiglitazone

Author(s) -

Tianli Yue,

Jun Chen,

Weike Bao,

Padma Kumar Narayanan,

Antoine Bril,

Wen Jiang,

Paul G. Lysko,

Juan-Li Gu,

Rogely Boyce,

Dawn Zimmerman,

Timothy K. Hart,

Robin E. Buckingham,

Eliot H. Ohlstein

Publication year - 2001

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/hc4601.099403

Subject(s) - medicine , rosiglitazone , ischemia , downregulation and upregulation , myocardial infarction , cardiology , reperfusion injury , reperfusion therapy , endocrinology , myocardial stunning , agonist , infarction , anesthesia , receptor , biochemistry , chemistry , gene

Diabetes is associated with increased risk of mortality as a consequence of acute myocardial infarction. This study determined whether rosiglitazone (ROSI) could reduce myocardial infarction after ischemia/reperfusion injury.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research